Eribulin in mTNBC Patients

An Observational, Retrospective Study of Eribulin in Advanced Breast Cancer

To evaluate the efficacy and safety of Eribulin in patients with advanced breast cancer.

Inclusion Criteria:

1. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
2. Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020.
3. Available medical history.

Exclusion Criteria:

1. Incomplete medical history.